CLColgate-Palmolive
$99.56+1.69%Delayed market dataConsumer staplesFood, beverage & household · 16 peers →Key levels and trade conditions
Delayed quotes · Technical conditionsShowing the near-term range, based on the latest 5 completed sessions and updated after each close.
Above the breakout line; await close and volume confirmation
Signals require closing-price and volume confirmation; review the company research below before acting.
When does defense take priority?
Close beyond this level with session volume ≥ 1.5× the previous 20 completed sessions’ average.
Confirmed close below $95.30 → consider reducing
When to consider adding?
Close beyond this level with session volume ≥ 1.5× the previous 20 completed sessions’ average.
Confirmed close above $99.08 → consider a staged addition
01Newstock overall assessment
The conclusion first, followed by the evidence that matters most.
Watch — await combined confirmation. An entry assessment has not yet been established.
02What happened recently
Company events, industry developments and market conditions — facts separated from possible explanations.
US 10Y yield 5.13%2026-11-13T16:29:34.000Z
VIX 20.122026-11-13T16:29:31.000Z
Dollar index 103.342026-11-13T16:34:40.000Z
Market and sector reference
CL +1.56% · SPY -1.01% · Peer average +1.81% (CLX, EL, GIS, HSY, KDP, KHC)
2026-11-13T16:34:07.000Z · Yahoo · Aligned-session reference, not a causal attribution.
Related news and impact paths
Recent news related to this stock
6 direct · 2 2nd-order · 0 thematicRanked by model assessment and recency. Labels use the original model impact, not expected returns. Impact percentages are model estimates, not observed price changes, probabilities or guaranteed returns.
- #1Impact2.7%FavorableDirectInflation Is Running Above 3%. These 3 Dividend Stocks Have the Pricing Power to Keep Up.9d ago
CL has strong brand stickiness in oral care and home care, and its high gross margin means price increases can be passed through without a severe hit to earnings.
Also named: PG · KMB · KO · PEP · MNST · WMT
The article directly names CL and highlights improving international growth, which can support revenue and margin if overseas volume and pricing gains continue.
Also named: PG · KMB · GIS · UL
As the headline name, Colgate’s performance in oral care, pet nutrition and its 60%+ gross margin directly drives expectations for quarterly profitability and full-year guidance.
Also named: PG · KMB · CHD · CLX · WMT · TGT
With a $20B+ revenue base and gross margin near 60%, a call that merely extends its recent ~3% beat pattern adds mostly margin resilience rather than demand upside, which still offers modest valuation support.
Also named: PG · UL · KMB
- #5Impact2%FavorableDirectColgate-Palmolive (CL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release21d ago
As the reporting company, another EPS beat would reinforce Colgate’s pricing power and margin resilience in oral care and other staples categories.
Also named: 宝洁 · 金佰利 · UL · NSRGY · DG · DLTR
- #6Impact2.8%FavorableDirectColgate-Palmolive: Improving Execution And A Valuation Discount Make It A Buy9d ago
The stock is explicitly upgraded to a buy on improving execution and a still-discounted valuation; continued execution gains could support a higher defensive multiple.
Also named: PG · KMB · CHD
- #7Impact0.9%Favorable2nd-orderClorox Q1 Earnings Beat Estimates on Higher Sales & Cost Savings10d ago
Investors may read Clorox’s beat as a sign of broader staples resilience, supporting other high-margin defensive consumer names.
Also named: CLX · PG · KMB · CHD
If industry input-cost pressure looks manageable, margin concerns across defensive consumer staples should ease, benefiting high-gross-margin household brands.
Also named: CLX · PG · KMB · KO · PEP · GIS
03Is the company worth considering?
Business quality, financials, valuation and analyst disagreements.
🏛️ Company factsSEC filings + FINRA official data
Annual revenue $20.4B · latest quarter up 4.6% YoY · reported FY net income of $2.1B · short-sale volume share near its recent available-day average.
FY revenue
$20.4B
2025-12
Latest Q YoY
+4.6%
Gross margin
60.1%
FY net income
$2.1B
Diluted EPS
$2.64
Short-sale volume share
51.4%
2026-11-05 · Recent available-day avg 55.2% · near recent average
Short-sale volume as a share of trades covered by the FINRA file, not all market trading or outstanding short positions. Changes do not establish that short sellers are adding or covering positions.
Historical results versus analyst expectations
🎯 Market expectations
Estimate context score High · 79/100Nasdaq analyst consensus · currently available data
- Sep 2026$0.97 vs $0.92+5.43%
- Jun 2026$0.99 vs $0.95+4.21%
- Mar 2026$0.97 vs $0.95+2.11%
- Dec 2025$0.95 vs $0.91+4.4%
The takeaway
EPS exceeded the corresponding consensus estimates by an average of 4% in the quarters shown. This is not a hurdle for the next report or a forecast of the stock's reaction. Analysts made 3 upward revisions over the past four weeks. Analysts made 3 downward revisions over the past four weeks.
Analyst estimates, not our forecast · not investment advice
Analyst consensus and disagreement
Target-price summary $95.00–$112.00 · Consensus $102.17
Buy / hold / sell 8 / 3 / 0
Nasdaq · Retrieved 2026-11-13T16:48:46.808Z · The aggregate does not provide individual report dates or original theses. It does not establish undervaluation; no analyst rationale is inferred. Targets are not guaranteed outcomes.
Next-quarter EPS estimate (Dec 2026) $0.98 · $0.96–$1.01 · 9 analysts
Four-week estimate revisions: up / down 3 / 3
Estimate dispersion 5.1%
Nasdaq EPS forecasts · retrieved 2026-11-13T16:48:44.753Z04Is now a good time?
Trend, moving averages, volume and key price levels — not the decline alone.
Technical structure · Uptrend structure
MA5 $97.70
MA10 $97.43
MA20 $95.56
MA60 $90.77
Last completed-session close $97.90 (-0.10%) · Volume / prior 20-session average 0.60×
Prior 20-session range $90.47–$101.18 · MA20 change over five sessions +1.86% · CMF20 0.07
- Low-volume pullback within an improving structure
Confirmation to watch: a close above $101.18 with volume at least 1.5× the prior 20-session average. A heavy-volume break below $90.47 weakens the setup.
Completed daily candles only. Daily OHLCV cannot establish accumulation, shakeout or manipulation intent; CMF is a price/volume proxy, not actual fund flows. Thresholds are research rules, not validated success probabilities. Yahoo · 2026-11-12
Price and news
Historical prices and volume. Drag to pan; scroll to zoom.
Related news
05What would change our assessment?
Conditions for reconsidering entry and developments that invalidate the thesis.
Complete the company and technical cross-check before defining entry and invalidation conditions.
Additional risk evidence and model detail
Market View
Crowding
Risk temperature
Tail risk
Triggers
Price and volume
Insider signals
See every affected stock, second-order impact and risk factor. Try Pro free for 7 days — no credit card required.
Start my free trial